Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma

ClinicalTrials.gov ID: NCT03469934

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03469934. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a proof of concept study designed to assess the effects of a single intravenous dose of etokimab compared to placebo in adult participants with severe eosinophilic asthma. This study will also assess the safety and tolerability of etokimab in adult participants with severe eosinophilic asthma.

Study identification

NCT ID: NCT03469934
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: AnaptysBio, Inc.; Industry
Enrollment: 25 participants

Conditions and interventions

Conditions

Eosinophilic Asthma

Interventions

Etokimab Biological
Placebo Drug

Biological · Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 14, 2017 (Actual)
Primary completion: Oct 30, 2018 (Actual)
Completion: Oct 30, 2018 (Actual)
Last update posted: Aug 16, 2023

2017 – 2018

United States locations

U.S. sites: 4
U.S. states: 4
U.S. cities: 4

Facility	City	State	ZIP	Site status
Midwest Allergy Sinus Asthma	Normal	Illinois	61761	—
Pulmonary & Critical Care Specialists	Novi	Michigan	48375	—
OK Clinical Research, LLC	Edmond	Oklahoma	73034	—
Allergy & Asthma Center of Southern Oregon	Medford	Oregon	97504	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03469934, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 16, 2023 · Synced Nov 15, 2026